AU5095885A - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
AU5095885A
AU5095885A AU50958/85A AU5095885A AU5095885A AU 5095885 A AU5095885 A AU 5095885A AU 50958/85 A AU50958/85 A AU 50958/85A AU 5095885 A AU5095885 A AU 5095885A AU 5095885 A AU5095885 A AU 5095885A
Authority
AU
Australia
Prior art keywords
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50958/85A
Inventor
Wolfgang Frohlich
Andreas Huth
Gerald Kirsch
Walter Klose
Henry Laurent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU5095885A publication Critical patent/AU5095885A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B1/00—Engines characterised by fuel-air mixture compression
    • F02B1/02—Engines characterised by fuel-air mixture compression with positive ignition
    • F02B1/04—Engines characterised by fuel-air mixture compression with positive ignition with fuel-air mixture admission into cylinder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU50958/85A 1984-10-19 1985-10-18 Pharmaceutical preparations Abandoned AU5095885A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19843438839 DE3438839A1 (en) 1984-10-19 1984-10-19 PHARMACEUTICAL PREPARATIONS
DE3438839 1984-10-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU47653/90A Division AU4765390A (en) 1984-10-19 1990-01-04 5(substituted phenyl) -2-oxazolidinones and use in pharmaceuticals.

Publications (1)

Publication Number Publication Date
AU5095885A true AU5095885A (en) 1986-05-02

Family

ID=6248597

Family Applications (2)

Application Number Title Priority Date Filing Date
AU50958/85A Abandoned AU5095885A (en) 1984-10-19 1985-10-18 Pharmaceutical preparations
AU47653/90A Abandoned AU4765390A (en) 1984-10-19 1990-01-04 5(substituted phenyl) -2-oxazolidinones and use in pharmaceuticals.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU47653/90A Abandoned AU4765390A (en) 1984-10-19 1990-01-04 5(substituted phenyl) -2-oxazolidinones and use in pharmaceuticals.

Country Status (8)

Country Link
EP (1) EP0198919B1 (en)
JP (2) JPH0742229B2 (en)
AU (2) AU5095885A (en)
DE (2) DE3438839A1 (en)
DK (1) DK167531B1 (en)
FI (1) FI862590A0 (en)
NO (1) NO164897C (en)
WO (1) WO1986002268A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
DE3639225A1 (en) * 1986-11-14 1988-05-19 Schering Ag USE OF 5- (SUBST. PHENYL) -OXAZOLIDINONE DERIATES AS PSYCHOPHARMAKA
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
ATE106243T1 (en) * 1988-03-24 1994-06-15 Sankyo Co USE OF ISOXAZOLINONES AS CEREBRO-ACTIVE MEDICATIONS.
DE69128627T2 (en) * 1990-08-03 1998-07-02 Smithkline Beecham Corp TNF INHIBITORS
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
JPH11500110A (en) * 1995-02-10 1999-01-06 シエーリング アクチエンゲゼルシヤフト TNF-suppressing preparation
DE19540475A1 (en) * 1995-10-20 1997-04-24 Schering Ag Chiral methylphenyloxazolidinones
US6770658B2 (en) * 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
RU2340600C2 (en) * 2001-10-16 2008-12-10 Мемори Фармасьютиклз Корпорейшн Derivatives of 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone as pde-4 inhibitors for treatment of neurological syndromes
WO2004098592A1 (en) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. Composition containing oxazolidinone derivative
TW200732313A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (en) * 1974-03-20 1975-10-16 Schering Ag 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE
DE2655369A1 (en) * 1976-12-03 1978-06-08 Schering Ag 5- (SUBST. PHENYL) -OXAZOLIDINONE AND THEIR SULFUR ANALOGS AND PROCESS FOR THEIR PRODUCTION
SU888821A3 (en) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Method of preparing 5-(substituted phehyl)-oxazolidinones or their sulphur-containing analogs

Also Published As

Publication number Publication date
NO164897C (en) 1990-11-28
JPH0742229B2 (en) 1995-05-10
NO164897B (en) 1990-08-20
WO1986002268A1 (en) 1986-04-24
JPS62501289A (en) 1987-05-21
NO862439D0 (en) 1986-06-18
DK167531B1 (en) 1993-11-15
DK288686A (en) 1986-06-19
FI862590A (en) 1986-06-17
EP0198919B1 (en) 1990-02-28
JP2669494B2 (en) 1997-10-27
DE3576118D1 (en) 1990-04-05
FI862590A0 (en) 1986-06-17
EP0198919A1 (en) 1986-10-29
DK288686D0 (en) 1986-06-19
JPH0761978A (en) 1995-03-07
DE3438839A1 (en) 1986-04-24
AU4765390A (en) 1990-05-03
NO862439L (en) 1986-06-18

Similar Documents

Publication Publication Date Title
AU6532586A (en) Pharmaceutical preparation
AU583585B2 (en) Etoposide preparations
AU5142485A (en) Cytotoxic protein
GB8518979D0 (en) Pharmaceutical preparation
GB8421706D0 (en) Pharmaceutical preparations
AU8317587A (en) Therapeutic preparations
AU4454389A (en) Pharmaceutical composition
CS419991A3 (en) Pharmaceutical preparations
AU7756487A (en) Pharmaceutical formulations
AU5095885A (en) Pharmaceutical preparations
EP0207451A3 (en) Pharmaceutical preparations
IL75921A0 (en) Gelatinous pharmaceutical preparations
AU4280985A (en) Dihydropyridine preparations
AU564632B2 (en) Pharmaceutical iodophor preparations
AU589637B2 (en) Fungicide preparations
AU584547B2 (en) Pharmaceutical `` -aminoalkyl- `` -alkylphenylacetonitriles
GB8520189D0 (en) Pharmaceutical preparations
GB8508443D0 (en) Pharmaceutical preparations
AU4280885A (en) Nifedipine preparations
AU7984487A (en) Pharmaceutical combination
AU2065588A (en) Pharmaceutical preparations for external use
AU6236090A (en) Pharmaceutical preparations
AU587505B2 (en) Pharmaceutical compositions
AU585011B2 (en) Rioprostil-PVP complex
AU5676286A (en) New medicine